Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
NVNovocure Ltd logo

Novocure Ltd (NVCR)

NASDAQ · Currency in USD
$14.68 ▼ -0.42 (-2.78%)
At close: Oct 23, 4:00 PM ET. Market closed.
$14.00 ▼ -0.68 (-4.63%)
After hours: Oct 23, 7:50 PM ET

Summary

Previous Close
$15.10
Open
$14.85
Day's Range
$14.53 – $14.97
52 Week Range
$9.82 – $21.45
Volume
1,125,126
Avg. Volume
1,527,726
Market Cap
$1.71B
Beta (5Y Monthly)
0.99
PE Ratio (TTM)
--
EPS (TTM)
-$1.28
Earnings Date
Oct 29, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$26.00

Profile: Novocure Ltd

Sector
Healthcare
Industry
Medical - Devices
Full-time employees
1,605
CEO
Frank Leonard

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

Earnings

Next report: Thu, Oct 29, 2026
EPS estimate -$0.23 · Revenue est. $182.28M
DateEst.Actual
Jul 23, 2026-$0.33-$0.13Beat
Apr 30, 2026-$0.51-$0.62Miss
Feb 26, 2026-$0.41-$0.22Beat
Oct 30, 2025-$0.42-$0.33Beat
Jul 24, 2025-$0.39-$0.36Beat
Apr 24, 2025-$0.47-$0.31Beat

Analyst view

Consensus price target
$26.00 ▲ +77.1%
Range $20.00 – $32.00
Rating: Buy
Buy 60% · Hold 33% · Sell 7%

Similar stocks

Get free alerts on NVCR and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.